Y Intercept Hong Kong Ltd Makes New $3.87 Million Investment in Lantheus Holdings, Inc. $LNTH

Y Intercept Hong Kong Ltd purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 75,382 shares of the medical equipment provider’s stock, valued at approximately $3,866,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Assenagon Asset Management S.A. bought a new position in Lantheus in the 3rd quarter worth about $65,654,000. Polaris Capital Management LLC bought a new stake in shares of Lantheus during the third quarter valued at about $32,687,000. Norges Bank purchased a new stake in shares of Lantheus in the second quarter worth about $32,631,000. Galvin Gaustad & Stein LLC bought a new position in shares of Lantheus in the second quarter valued at approximately $11,899,000. Finally, Boston Partners grew its stake in Lantheus by 30.5% during the second quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock valued at $46,432,000 after acquiring an additional 134,781 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Mizuho increased their target price on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Truist Financial boosted their target price on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Stock Performance

NASDAQ LNTH opened at $67.51 on Monday. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $111.29. The company has a fifty day moving average of $63.52 and a 200-day moving average of $60.26. The company has a market capitalization of $4.48 billion, a P/E ratio of 28.37 and a beta of -0.11. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.27. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. During the same quarter last year, the business posted $1.70 earnings per share. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.